Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.78 |
| ▸ | TYK2 | P29597 | 20/20 | 0.78 |
| ▸ | JAK2 | O60674 | 15/20 | 0.78 |
| ▸ | PDE4D | Q08499 | 7/20 | 0.78 |
| ▸ | JAK3 | P52333 | 6/20 | 0.59 |
| ▸ | KIT | P10721 | 2/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30392443 | 1.00 | JAK1 (0.78) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL30392604 | 0.92 | JAK1 (0.78) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL26100551 | 0.92 | JAK1 (0.78) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL26462437 | 0.88 | JAK1 (0.81) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL17689128 | 0.88 | JAK1 (1.00) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL26102435 | 0.86 | JAK1 (0.71) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL30392702 | 0.86 | JAK1 (0.71) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL26102771 | 0.85 | TYK2 (0.78) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL26101128 | 0.85 | JAK1 (0.57) | JAK1TYK2JAK2PDE4DJAK3 | |
| SCHEMBL31161576 | 0.84 | TYK2 (0.64) | JAK1TYK2JAK2PDE4DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
| EP-4423086-A1 | TYK2 DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076161-A1 | TYK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051338-A1 | TYK2 DEGRADERS AND USES THEREOF | TYK2, DYRK2, DYRK1A | JAK1 66/4885TYK2 1/4885JAK2 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.